Luminity

RSS

perflutren

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 29/06/2022

Authorisation details

Product details
Name
Luminity
Agency product number
EMEA/H/C/000654
Active substance
perflutren
International non-proprietary name (INN) or common name
perflutren
Therapeutic area (MeSH)
Echocardiography
Anatomical therapeutic chemical (ATC) code
V08DA04
Publication details
Marketing-authorisation holder
Lantheus EU Limited
Revision
16
Date of issue of marketing authorisation valid throughout the European Union
20/09/2006
Contact address

Atlantic Avenue
Westpark Business Campus
Shannon
Co. Clare
Ireland

Product information

19/05/2022 Luminity - EMEA/H/C/000654 - II/0039

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Contrast media

Therapeutic indication

This medicinal product is for diagnostic use only.

Luminity is an ultrasound contrast-enhancing agent for use in patients in whom non-contrast echocardiography was suboptimal (suboptimal is considered to indicate that at least two of six segments in the 4- or 2-chamber view of the ventricular border were not evaluable) and who have suspected or established coronary artery disease, to provide opacification of cardiac chambers and improvement of left ventricular endocardial border delineation at both rest and stress.

Assessment history

How useful was this page?

Add your rating